About This Companion

What Peptide Friend is

Peptide Friend is a plain-spoken companion to the published research on three peptides that keep coming up in talk about cognition, mood, anxiety and sleep: Semax, Selank, and DSIP, with Selank as the lead compound. The friendly part is the tone, not the conclusions: the aim is to tell a reader, in plain language and with citations, what each compound was actually studied for, in which species, and how far that evidence honestly reaches — through a scattered, often geographically concentrated, and frequently overstated literature.

The organizing approach is an honest three-way comparison. Selank has the most direct human clinical data among the three (a small Russian generalized-anxiety trial). Semax has the deepest rodent mechanistic record and a prescription registration in Russia. DSIP has the longest history and the weakest mechanistic resolution, with a 2006 mainstream review describing its sleep evidence as extremely poorly documented. Each compound gets its own page; a comparison page lines them up; and a shared references list aggregates every source cited across the site.

Community-reported experiences — what people in nootropic forums and peptide communities say they observe — are included on the per-compound pages where the source material contains them, clearly labeled as anecdotal and kept separate from the cited research findings. That distinction is not a formality. It is the substance of what this site offers: knowing where the clinical record stops and community experience begins.

How it is compiled

Three rules govern what appears here.

One — everything is anchored to the peer-reviewed literature. Each research claim carries a numbered citation — journal articles and reviews indexed in PubMed or equivalent databases, with DOIs or PubMed links — collected on the references page. A finding drawn from a review rather than a primary study is cited as a review.

Two — the evidence is described at its actual strength. Doses are reported the way studies state them: studied at 50 micrograms per kilogram in rats, or in six chronic insomniacs in a 1981 pilot trial. Where evidence is preclinical, single-lab, from a single geographic tradition, or rests on analogs rather than the marketed compound, the page says so. Candor about limits is not a hedge — it is the accurate description of the record.

Three — the three pages are cross-referenced. The same themes — neurotrophin signaling, GABA modulation, enkephalinase inhibition, neuroendocrine effects — recur across compounds, and the pages link to one another so a reader can trace a mechanism from one peptide to the next.

What it is not

For all its friendly name, Peptide Friend is no store, no clinic, and no source of medical advice. It sells, supplies, sources, and brokers no peptide or research chemical, and holds no affiliate or referral tie to any vendor. It keeps no clinicians, diagnoses no condition, and prescribes nothing. It recommends no dose, schedule, or route of administration for anyone, and never presents an animal-study dose as something a human should take.

The peptides here are research compounds. None is an approved medicine for human use in the United States or European Union. Two are registered prescription drugs in Russia only — which counts for their clinical history but is not FDA or EMA approval. One has no approved therapeutic registration anywhere. Anyone drawn to a condition described in the underlying research — anxiety, sleep disorders, cognitive impairment — should consult a licensed clinician in their own jurisdiction, working with regulated, evidence-based options. What this site offers is a calm, accurate map of the literature — not more, and not pretending to be.